Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWAND.L Regulatory News (WAND)

  • There is currently no data for WAND

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board Update

23 Feb 2017 07:00

RNS Number : 6400X
WANdisco Plc
23 February 2017
 

23 February 2017

WANdisco plc

("WANdisco" or the "Company")

 

Board update

 

WANdisco (LSE: WAND), the world leader in Active Data Replication™ today announces the following board changes.

 

Dr Yeturu Aahlad, 58, who is part of the core team that founded WANdisco in 2005, is appointed to the board with immediate effect. Dr Aahlad is a pioneer in the field of active-active data replication, a patented process that sits at the heart of WANdisco's core technology, WANdisco Fusion. Dr Aahlad has a Ph.D in the field of Distributed Computing from the University of Texas, Austin and a BS in Electronics and Communication from IIT Madras.

 

In addition, the Company announces that James (Jim) Campigli, Chief Operating Officer, Head of Marketing, Co-Founder and member of the board will be stepping down with immediate effect to pursue other business interests. He leaves with the board's thanks for the significant contribution he has made since WANdisco's inception.

 

David Richards, Chief Executive Officer and Interim Chairman of WANdisco, commented:

 

"We are delighted to welcome Dr Aahlad to the board. As a founder and pioneer of WANdisco's patented technology, he is a natural addition and we believe he offers a wealth of industry experience which will be invaluable as we implement our near term growth strategy. I would also like to thank Jim for his tremendous contribution in the development of WANdisco and wish him well in all his future endeavours."

 

Dr Aahlad currently has a beneficial holding of 2,825,021 Ordinary Shares in the Company representing 7.62% of the Company's issued share capital.

 

There are no further disclosures required relating to Dr Aahlad's appointment in accordance with Schedule 2(g) of the AIM Rules.

 

For further information, please contact:

 

WANdisco plc

via Vigo Communications

David Richards, Chief Executive Officer and Interim Chairman

 

Erik Miller, Chief Financial Officer

 

Vigo Communications

+44 (0)207 830 9707

Jeremy Garcia / Fiona Henson / Antonia Pollock

www.vigocomms.com

Stifel (Joint Broker and Nomad)

+44 (0)207 710 7600

Fred Walsh / Neil Shah / Ben Maddison / Rajpal Padam

 

 

 

UBS (Joint Broker)

Rahul Luthra / Sandip Dhillon

+44 (0)207 567 8000

 

About WANdisco

 

WANdisco (LSE: WAND) is the world leader in Active Data Replication™. Its patented technology provides continuous consistent access to changing data anytime and anywhere with no downtime and no disruption. WANdisco's patented technology serves crucial high availability (HA) requirements, including migration to cloud, Hadoop Big Data and Application Lifecycle Management (ALM), Subversion, Git and Gerrit. 

 

WANdisco works directly with Fortune 1000 companies around the world and in all sectors to ensure their data, whether it is on-premise or in the cloud, gives them the real insight they need. WANdisco has an OEM with IBM and is also partnered with Amazon Web Services, Cisco, Google Cloud Platform, Hewlett Packard Enterprise, Microsoft Azure and Oracle to resell its patented technology. WANdisco is committed to the ODPi Interoperable Compliance Program to ensure its products are interoperable across a wider range of commercial Apache™ Hadoop® Platforms.

 

For additional information, please visit www.wandisco.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALIFFRFSIVFID
Date   Source Headline
4th Oct 20237:00 amRNSWANdisco plc rebrands as Cirata plc
22nd Sep 20236:24 pmRNSHolding(s) in Company
11th Sep 20237:00 amRNSInterim results
7th Sep 20233:30 pmRNSNotice of Results
30th Aug 20236:04 pmRNSResult of Annual General Meeting
18th Aug 20236:05 pmRNSBlock Admission Notification
16th Aug 20238:07 amRNSGM Signs Multi-Project Contract with WANdisco
31st Jul 20237:00 amRNSHolding(s) in Company
28th Jul 20233:25 pmRNSHolding(s) in Company
26th Jul 20237:00 amRNSBoard Changes
25th Jul 20237:30 amRNSRestoration - WANdisco plc
25th Jul 20237:00 amRNSConfirmation of Exchange Rate
24th Jul 202310:45 amRNSResult of GM
17th Jul 20235:00 pmRNSPosting of Annual Report and Accounts
12th Jul 20231:45 pmRNSPublication of Annual Report and Accounts
11th Jul 20237:00 amRNSContract Win
10th Jul 20237:00 amRNSContract Renewal
7th Jul 20237:00 amRNSConfirmation of Fundraise
5th Jul 20236:29 pmRNSPublication of Notice of General Meeting
5th Jul 202311:30 amRNSUpdate to Fundraise Timetable
4th Jul 20237:00 amRNSResult of Fundraising
3rd Jul 202312:00 pmRNSLaunch of Fundraise
29th Jun 20237:00 amRNSPreliminary Unaudited Results FY22
28th Jun 202311:51 amRNSUpdate on Timing of Results and Equity Issue
26th Jun 20233:30 pmRNSTurnaround Plan Momentum
26th Jun 20237:00 amRNSWANdisco Signs New Agreement with Accenture
15th Jun 20239:46 amRNSFCA investigation timeline update
9th Jun 20237:00 amRNSSuccessful Shareholder General Meeting Next Steps
6th Jun 20233:49 pmRNSResult of General Meeting
19th May 20236:22 pmRNSPublication of Circular and Notice of GM
19th May 20236:04 pmRNSBoard Change
15th May 20237:00 amRNSExploring Funding Options
9th May 20235:30 pmRNSWANdisco
9th May 20237:00 amRNSAppointment of Interim Chief Executive
4th May 20237:00 amRNSOrganisation Update
28th Apr 20237:00 amRNSIndependent Investigation Update
20th Apr 20237:00 amRNSFCA Investigation
5th Apr 20237:00 amRNSExecutive Chair Appointment Confirmation
4th Apr 20237:00 amRNSContract Renewals
3rd Apr 20237:00 amRNSBoard Change and Investigation Update
22nd Mar 20237:00 amRNSAppointment of Interim Chair
10th Mar 20239:31 amRNSIndependent Investigation Appointment
9th Mar 20237:30 amRNSSuspension - WANdisco plc
9th Mar 20237:00 amRNSTrading Revision
7th Mar 20237:00 amRNSAppointment of Joint Broker
6th Mar 20237:00 amRNSResponse to press speculation
1st Mar 20238:16 amRNSTotal Voting Rights
1st Feb 20234:05 pmRNSTotal Voting Rights
24th Jan 20237:00 amRNS$9m industrial and consumer goods contract win
11th Jan 20237:00 amRNSFY22 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.